Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
Fintel reports that on November 18, 2025, B of A Securities maintained coverage of Werewolf Therapeutics (NasdaqGS:HOWL) with a Buy recommendation. As of November 17, 2025, the average one-year price ...
On December 18, 2025, Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shared a comprehensive pipeline update in which it highlighted clinical progress and 2026 priorities for its INDUKINE programs and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results